STERIALS

A biopharmaceutical company that acquires and develops drugs to treat autoimmune diseases. The company is developing subcutaneous peptides as a treatment for chronic autoimmune diseases such as systemic lupus erythematosus, Sjogren's syndrome, and kidney, central nervous system, heart, and blood systems. The company expects the effects of the treatment to be due to upstream immune regulation through the generation of regulatory T cells, suppression of inflammation, and restoration of immune balance.